Discontinuation report BYDUREON
Report ID | 153603 |
Drug Identification Number | 02448610 |
Brand name | BYDUREON |
Common or Proper name | exenatide for extended-release injectable suspension |
Company Name | ASTRAZENECA CANADA INC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | EXENATIDE |
Strength(s) | 2MG |
Dosage form(s) | KIT POWDER FOR SUSPENSION, EXTENDED-RELEASE |
Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
Packaging size | 4 single dose pens |
ATC code | A10BJ |
ATC description | BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | 2022-03-31 |
Actual discontinuation date | 2022-03-31 |
Remaining supply date | 2022-10-31 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | The remaining product supply will provide coverage for approximately 1 month from discontinuation date. |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Company contact information | Please contact AstraZeneca Canada Medical Information for any specific questions at 1-800-668-6000 (EN) or 1-800-461-3787 (FR) or by email: medinfo.canada@astrazeneca.com. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2022-04-01 | English | Compare |
v5 | 2022-01-28 | French | Compare |
v4 | 2022-01-28 | English | Compare |
v3 | 2022-01-26 | French | Compare |
v2 | 2022-01-26 | English | Compare |
v1 | 2022-01-26 | English | Compare |
Showing 1 to 6 of 6